Cargando…

Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer

miRNA plays an important role in tumourgenesis by regulating expression of oncogenes and tumour suppressors. Thus affects cell proliferation and differentiation, apoptosis, invasion and angiogenesis. miRNAs are potential biomarkers for diagnosis, prognosis and therapies of different forms of cancer....

Descripción completa

Detalles Bibliográficos
Autores principales:	Deyati, Avisek, Bagewadi, Shweta, Senger, Philipp, Hofmann-Apitius, Martin, Novac, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389028/ https://www.ncbi.nlm.nih.gov/pubmed/25622824 http://dx.doi.org/10.1038/srep08013

Ejemplares similares

NeuroRDF: semantic integration of highly curated data to prioritize biomarker candidates in Alzheimer's disease
por: Iyappan, Anandhi, et al.
Publicado: (2016)

Linking hypothetical knowledge patterns to disease molecular signatures for biomarker discovery in Alzheimer’s disease
por: Malhotra, Ashutosh, et al.
Publicado: (2014)

Analytical Strategy to Prioritize Alzheimer’s Disease Candidate Genes in Gene Regulatory Networks Using Public Expression Data
por: Kawalia, Shweta Bagewadi, et al.
Publicado: (2017)

NeuroTransDB: highly curated and structured transcriptomic metadata for neurodegenerative diseases
por: Bagewadi, Shweta, et al.
Publicado: (2015)

Detecting miRNA Mentions and Relations in Biomedical Literature
por: Bagewadi, Shweta, et al.
Publicado: (2015)

Mining biomarker information in biomedical literature
por: Younesi, Erfan, et al.
Publicado: (2012)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
por: Yang, Zu-Yao, et al.
Publicado: (2012)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
por: Shinozaki, Eiji, et al.
Publicado: (2017)

MicroRNAs as Biomarkers in Colorectal Cancer
por: Masuda, Takaaki, et al.
Publicado: (2017)

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
por: Dankner, Matthew, et al.
Publicado: (2018)

Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
por: Shinozaki, Eiji, et al.
Publicado: (2018)

MicroRNAs as Novel Biomarkers in Colorectal Cancer
por: Hrašovec, Sonja, et al.
Publicado: (2012)

Biomarkers for Stratification in Colorectal Cancer: MicroRNAs
por: Fadaka, Adewale Oluwaseun, et al.
Publicado: (2019)

Editorial: MicroRNAs as biomarkers in colorectal cancer
por: Ulivi, Paola
Publicado: (2023)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
por: Bonomi, P D, et al.
Publicado: (2018)

Germline Polymorphisms as Biomarkers of Tumor Response in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies: A Systematic Review and Meta-Analysis
por: Morgen, Eric K, et al.
Publicado: (2017)

Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
por: Mao, C, et al.
Publicado: (2010)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
por: Kang, Sora, et al.
Publicado: (2023)

Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response
por: Kirouac, Daniel C., et al.
Publicado: (2023)

Deconvolution of clinical variance in CAR-T cell pharmacology and response
por: Kirouac, Daniel C., et al.
Publicado: (2023)

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

Rare Circulating MicroRNAs as Biomarkers of Colorectal Neoplasia
por: Adams, Scott V., et al.
Publicado: (2014)

Circulating microRNAs as Promising Biomarkers in Colorectal Cancer
por: Rapado-González, Óscar, et al.
Publicado: (2019)

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Lu, Xiaona, et al.
Publicado: (2023)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

MicroRNAs as non-invasive screening biomarkers of colorectal cancer
por: SAPLACAN, ROBERTA MARIA MANZAT, et al.
Publicado: (2015)

Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer
por: Yan, Shushan, et al.
Publicado: (2017)

MicroRNAs: promising biomarkers for diagnosis and therapeutic targets in human colorectal cancer metastasis
por: Hur, Keun
Publicado: (2015)

Potential roles of microRNAs and ROS in colorectal cancer: diagnostic biomarkers and therapeutic targets
por: Lin, Jingmei, et al.
Publicado: (2017)

MicroRNAs in blood act as biomarkers of colorectal cancer and indicate potential therapeutic targets
por: Stang, Axel, et al.
Publicado: (2021)

The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
por: Yuan, Zi-Xu, et al.
Publicado: (2013)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
por: Kaneko, Mika K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8l2ai3qv5os1j9cce9oplvds02